4º Simpósio Médico Anual do ECD Paris, França

abr 1, 2016 | Simpósio Médico

Localização: Paris, França

Resumo das apresentações

Apresentações

As apresentações a seguir foram feitas na reunião de 2016. Acesse o canal do YouTube daECD Global Alliance para ver todos os vídeos publicados relacionados à ECD.

Presenter	Presentation Slides	Videos
Corrado Campochiaro, MD	Management of ECD Symptoms and Side Effects of Treatments	Management of ECD Symptoms and Side Effects of Treatments
Giulio Cavalli, MD	Adult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester Disease	Adult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester Disease
Carine Courtillot, MD	Endocrine manifestations in Erdheim-Chester disease	Endocrine manifestations in Erdheim-Chester disease
Benjamin Durham, MD	Insights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine Models	Insights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine Models
Marina Ferrarini, MD	Tailoring Treatment for Erdheim-Chester Disease: Focus on ECD	Tailoring Treatment for Erdheim-Chester Disease: Focus on ECD
Ronald Go, MD	Efficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD)	Efficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD)
Filip Janku, MD, PhD	Encouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease	Encouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease
Javier Martin, MD, PhD	Future Genetic Studies in Erdheim-Chester disease – GWAS Study	Future Genetic Studies in Erdheim-Chester disease – GWAS Study
Kenneth McClain, MD, PhD	Elevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD?	Elevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD?
Augusto Vaglio, MD, PhD	MRI evidence of cardiac involvement in Erdheim-Chester disease	MRI evidence of cardiac involvement in Erdheim-Chester disease